Regenxbio (NASDAQ:RGNX) posted its earnings results on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.93), Bloomberg Earnings reports. Regenxbio had a net margin of 37.28% and a return on equity of 23.27%. The business had revenue of $40.03 million during the quarter, compared to analysts’ expectations of $100.00 million.
NASDAQ RGNX traded up $0.70 on Friday, hitting $67.40. 2,050,400 shares of the stock were exchanged, compared to its average volume of 552,838. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -26.43, a PEG ratio of 1.83 and a beta of -1.16. Regenxbio has a 52-week low of $19.45 and a 52-week high of $85.10.
Several research analysts have commented on the stock. BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 1st. Raymond James set a $45.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Chardan Capital lifted their price objective on shares of Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, July 16th. TheStreet raised shares of Regenxbio from a “d+” rating to a “c” rating in a research note on Friday, May 11th. Finally, Barclays reaffirmed an “overweight” rating and set a $48.00 price objective (up from $38.00) on shares of Regenxbio in a research note on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Regenxbio has an average rating of “Buy” and a consensus price target of $64.19.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.